Clinical Trial Goal
To find out if the combination of melphalan and siltuximab is safe and works well to treat multiple myeloma
You may be able to join this trial if you:
- Are 60 years old or older
- Have multiple myeloma and plan on having an autologous BMT
- Have not been treated with a drug that targets IL-6. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Melphalan is a drug that blocks the growth of cancer cells.
Siltuximab is a monoclonal antibody that blocks IL-6 on certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Siltuximab is a monoclonal antibody that blocks IL-6 on certain cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
- Group 1 – Melphalan
- Group 2 – Melphalan plus siltuximab
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
- Melphalan – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Siltuximab – Group 2 only - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working.
The Food and Drug Administration (FDA) has approved melphalan to treat multiple myeloma. The FDA has approved siltuximab to treat multicentric Castleman's disease. Using it in this way to treat multiple myeloma in older adults before autologous BMT, is new and unproven.
Locations
Sponsors
collaborator: RECORDATI GROUP, lead: Memorial Sloan Kettering Cancer Center
